VHL Polyclonal Antibody

Ab type

Primary antibody

Background

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of VHL is the basis of familial inheritance of VHL syndrome. The protein encoded by VHL is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.

Reactivity

Human;Mouse;Rat

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Immunogen

The antiserum was produced against synthesized peptide derived from human VHL. AA range:34-83

Storage Stability

-20°C for one year

Concentration

1 mg/ml

MolecularWeight_Da

24153

synonyms

VHL; Von Hippel-Lindau disease tumor suppressor; Protein G7; pVHL